Imatinib is a first-line therapy for chronic myeloid leukemia (CML), a form of cancer caused by chromosomal fusion of BCR and ABL1 (Ren, 2005). This evidence concerns the gene ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive.